Why Inovio Stock Is Crashing Today_老虎社区_美港股上老虎

Why Inovio Stock Is Crashing Today

Motley Fool 2021-04-23

The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate. What happened Shares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

235

JaydenSee
·2021-04-25
Pls like and comments
回复
2
举报
收起
- Milkgonebad:
  k
  2021-04-25
  回复
  举报
- EV8:
  👍👍
  2021-04-25
  回复
  举报
- JaydenSee:
  thanks
  2021-04-26
  回复
  举报
查看更多 1 条评论
Goldox
·2021-04-25
Gg
回复
点赞
举报
猛虎不是病猫
·2021-04-25
[微笑]
回复
3
举报
收起
- The knights:
  ??? Why??
  2021-04-25
  回复
  举报
- Werkohderkoh:
  😮
  2021-04-25
  回复
  举报
- 猛虎不是病猫:
  [Speechless]
  2021-04-25
  回复
  举报
查看更多 2 条评论
S土豪熊貓G
·2021-04-25
Pls comments and likes. Thanks!
回复
3
举报
收起
- Huat99:
  okok
  2021-04-25
  回复
  举报
- S土豪熊貓G:
  Thanks Huat99
  2021-04-25
  回复
  举报
AndyQuak
·2021-04-25
Comment thanks
回复
2
举报
收起
- JBSIEW:
  Good day.
  2021-04-25
  回复
  举报
JBSIEW
·2021-04-25
Up fast, down also fast. Even Pfizer's price also not up more than 30%.
回复
3
举报
收起
- AndyQuak:
  comment thanks
  2021-04-25
  回复
  举报
BeHappy
·2021-04-25
I have no idea
回复
3
举报
Jusdidas
·2021-04-25
Please like and comment!
回复
2
举报
收起
- Sandy92:
  done. please like and comment back
  2021-04-25
  回复
  举报
458fd99c
·2021-04-25
Why not
回复
2
举报
knowplay
·2021-04-24
Good
回复
点赞
举报
Poisonz
·2021-04-24
Lol
回复
点赞
举报
Crip
·2021-04-24
Joke
回复
6
举报
收起
- hellotomato:
  :/
  2021-04-24
  回复
  举报
DogeFather69
·2021-04-24
Wtf
回复
2
举报
mr_tig3r
·2021-04-24
Ok
回复
3
举报
xuanlin
·2021-04-24
Comment pls
回复
1
举报
收起
- Qarah:
  Done!
  2021-04-25
  回复
  举报
justinC
·2021-04-24
Like and commment please
回复
2
举报
收起
- justinC:
  ple
  2021-04-24
  回复
  举报
dahae
·2021-04-24
comment pls
回复
3
举报
收起
- pandajojo:
  Like n comment
  2021-04-25
  回复
  举报
- dahae:
  .
  2021-04-25
  回复
  举报
- dahae:
  .
  2021-04-25
  回复
  举报
Ivylow
·2021-04-24
👍
回复
1
举报
Ivylow
·2021-04-24
$
回复
点赞
举报
Ivylow
·2021-04-24
👍
回复
点赞
举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1122047796?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-04-23 23:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122047796","market":"us","top_or_hot":-1,"title":"Why Inovio Stock Is Crashing Today","media":" Motley Fool ","content":"<div>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/> Motley Fool </a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INO","symbol_name":"伊诺维奥制药","start_time":0,"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","article_id":"1122047796","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","pubTimestamp":1619190353,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"INO":"伊诺维奥制药"},"translate_title":"为什么Inovio股票今天暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INO":0.9},"content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","kind":"news","is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":375138361,"gmtCreate":1619314440653,"gmtModify":1634274328859,"author":{"id":"3571546243427161","authorId":"3571546243427161","name":"JaydenSee","avatar":"https://static.tigerbbs.com/f81b1d1b9ef76e9028b0f68e5a5d3553","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3571546243427161","authorIdStr":"3571546243427161"},"htmlText":"Pls like and comments&nbsp;","listText":"Pls like and comments&nbsp;","text":"Pls like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/375138361","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://www.laohu8.com/m/news/1122047796?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\n Motley Fool 2021-04-23 23:05\n\n</h4>\n</header>\n<article>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\"> Motley Fool </a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1,"symbols_score_info":{"INO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4125671,"gmtCreate":1619314896606,"gmtModify":1635512041036,"authorId":3576484544353713,"author":{"id":3576484544353713,"idStr":"3576484544353713","authorId":3576484544353713,"name":"Milkgonebad","avatar":"https://static.tigerbbs.com/13596b6d0ccd5ec5f1323ca987d7ae85","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375138361,"type":1,"supId":0,"prevId":0,"content":"k","text":"k","html":"k"},{"id":4130172,"gmtCreate":1619356532270,"gmtModify":1635511612813,"authorId":3576472032670521,"author":{"id":3576472032670521,"idStr":"3576472032670521","authorId":3576472032670521,"name":"EV8","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375138361,"type":1,"supId":0,"prevId":0,"content":"👍👍","text":"👍👍","html":"👍👍"},{"id":4135857,"gmtCreate":1619414609297,"gmtModify":1635511077607,"authorId":3571546243427161,"author":{"id":3571546243427161,"idStr":"3571546243427161","authorId":3571546243427161,"name":"JaydenSee","avatar":"https://static.tigerbbs.com/f81b1d1b9ef76e9028b0f68e5a5d3553","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375138361,"type":1,"supId":4130172,"prevId":0,"content":"thanks","text":"thanks","html":"thanks"},{"id":4140507,"gmtCreate":1619452821402,"gmtModify":1635510718548,"authorId":3573385929982547,"author":{"id":3573385929982547,"idStr":"3573385929982547","authorId":3573385929982547,"name":"3a5bc973","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375138361,"type":1,"supId":0,"prevId":0,"content":"Same","text":"Same","html":"Same"}],"langContent":"EN"},{"id":375375483,"gmtCreate":1619312743342,"gmtModify":1634274350153,"author":{"id":"3574248655626938","authorId":"3574248655626938","name":"Goldox","avatar":"https://static.tigerbbs.com/863110a9408a00f21e04f570ea1c03f2","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3574248655626938","authorIdStr":"3574248655626938"},"htmlText":"Gg","listText":"Gg","text":"Gg","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/375375483","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://www.laohu8.com/m/news/1122047796?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\n Motley Fool 2021-04-23 23:05\n\n</h4>\n</header>\n<article>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\"> Motley Fool </a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1,"symbols_score_info":{"INO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":375347083,"gmtCreate":1619312338142,"gmtModify":1634274358794,"author":{"id":"3570880740385047","authorId":"3570880740385047","name":"猛虎不是病猫","avatar":"https://static.tigerbbs.com/525c8e91071a31355d14f58b858ff9dc","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3570880740385047","authorIdStr":"3570880740385047"},"htmlText":"[微笑]&nbsp;","listText":"[微笑]&nbsp;","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/375347083","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://www.laohu8.com/m/news/1122047796?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\n Motley Fool 2021-04-23 23:05\n\n</h4>\n</header>\n<article>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\"> Motley Fool </a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1,"symbols_score_info":{"INO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4126678,"gmtCreate":1619321450120,"gmtModify":1635511948162,"authorId":3570437600969291,"author":{"id":3570437600969291,"idStr":"3570437600969291","authorId":3570437600969291,"name":"The knights","avatar":"https://static.tigerbbs.com/75dcd9b9c7a6f69cb6e3d99df5c339df","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375347083,"type":1,"supId":0,"prevId":0,"content":"??? Why??","text":"??? Why??","html":"??? Why??"},{"id":4127033,"gmtCreate":1619323378987,"gmtModify":1635511910717,"authorId":3571138623117037,"author":{"id":3571138623117037,"idStr":"3571138623117037","authorId":3571138623117037,"name":"Werkohderkoh","avatar":"https://static.tigerbbs.com/15f00b0aef0edf959d4cceebd1513729","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375347083,"type":1,"supId":0,"prevId":0,"content":"😮","text":"😮","html":"😮"},{"id":4127429,"gmtCreate":1619327148758,"gmtModify":1635511872576,"authorId":3570880740385047,"author":{"id":3570880740385047,"idStr":"3570880740385047","authorId":3570880740385047,"name":"猛虎不是病猫","avatar":"https://static.tigerbbs.com/525c8e91071a31355d14f58b858ff9dc","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375347083,"type":1,"supId":4127033,"prevId":0,"content":"[Speechless]","text":"[Speechless]","html":"[Speechless]"},{"id":4127430,"gmtCreate":1619327156315,"gmtModify":1635511872452,"authorId":3570880740385047,"author":{"id":3570880740385047,"idStr":"3570880740385047","authorId":3570880740385047,"name":"猛虎不是病猫","avatar":"https://static.tigerbbs.com/525c8e91071a31355d14f58b858ff9dc","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375347083,"type":1,"supId":4126678,"prevId":0,"content":"[Speechless]","text":"[Speechless]","html":"[Speechless]"},{"id":4142837,"gmtCreate":1619480287832,"gmtModify":1635510528817,"authorId":3570437600969291,"author":{"id":3570437600969291,"idStr":"3570437600969291","authorId":3570437600969291,"name":"The knights","avatar":"https://static.tigerbbs.com/75dcd9b9c7a6f69cb6e3d99df5c339df","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375347083,"type":1,"supId":0,"prevId":0,"content":"Buy Or not","text":"Buy Or not","html":"Buy Or not"}],"langContent":"CN"},{"id":375354935,"gmtCreate":1619311665327,"gmtModify":1634274367764,"author":{"id":"3578811676095048","authorId":"3578811676095048","name":"S土豪熊貓G","avatar":"https://static.tigerbbs.com/2bf36dcb8e5b590c1e5f4df466413275","vip":1,"crmLevel":9,"crmLevelSwitch":0,"idStr":"3578811676095048","authorIdStr":"3578811676095048"},"htmlText":"Pls comments and likes. Thanks!","listText":"Pls comments and likes. Thanks!","text":"Pls comments and likes. Thanks!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/375354935","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://www.laohu8.com/m/news/1122047796?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\n Motley Fool 2021-04-23 23:05\n\n</h4>\n</header>\n<article>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\"> Motley Fool </a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1,"symbols_score_info":{"INO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4125101,"gmtCreate":1619312169817,"gmtModify":1635512095673,"authorId":3555376654101817,"author":{"id":3555376654101817,"idStr":"3555376654101817","authorId":3555376654101817,"name":"Huat99","avatar":"https://static.tigerbbs.com/2c30eb3331cf3fbbc42818b462456369","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375354935,"type":1,"supId":0,"prevId":0,"content":"okok","text":"okok","html":"okok"},{"id":4126666,"gmtCreate":1619321327058,"gmtModify":1635511949272,"authorId":3578811676095048,"author":{"id":3578811676095048,"idStr":"3578811676095048","authorId":3578811676095048,"name":"S土豪熊貓G","avatar":"https://static.tigerbbs.com/2bf36dcb8e5b590c1e5f4df466413275","vip":1,"crmLevel":9,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375354935,"type":1,"supId":4125101,"prevId":0,"content":"Thanks Huat99","text":"Thanks Huat99","html":"Thanks Huat99"}],"langContent":"EN"},{"id":375382126,"gmtCreate":1619308925265,"gmtModify":1634287241597,"author":{"id":"3576709266160370","authorId":"3576709266160370","name":"AndyQuak","avatar":"https://static.tigerbbs.com/bd9f635e190b833549d9282c6e3e2f59","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3576709266160370","authorIdStr":"3576709266160370"},"htmlText":"Comment thanks&nbsp;","listText":"Comment thanks&nbsp;","text":"Comment thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/375382126","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://www.laohu8.com/m/news/1122047796?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\n Motley Fool 2021-04-23 23:05\n\n</h4>\n</header>\n<article>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\"> Motley Fool </a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1,"symbols_score_info":{"INO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4124627,"gmtCreate":1619309853233,"gmtModify":1635512142644,"authorId":3563244604368605,"author":{"id":3563244604368605,"idStr":"3563244604368605","authorId":3563244604368605,"name":"JBSIEW","avatar":"https://static.tigerbbs.com/98de4f8fefba82ae441dde7b51ef936d","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375382126,"type":1,"supId":0,"prevId":0,"content":"Good day.","text":"Good day.","html":"Good day."}],"langContent":"EN"},{"id":375314661,"gmtCreate":1619307958953,"gmtModify":1634287247693,"author":{"id":"3563244604368605","authorId":"3563244604368605","name":"JBSIEW","avatar":"https://static.tigerbbs.com/98de4f8fefba82ae441dde7b51ef936d","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3563244604368605","authorIdStr":"3563244604368605"},"htmlText":"Up fast, down also fast. Even Pfizer's price also not up more than 30%.","listText":"Up fast, down also fast. Even Pfizer's price also not up more than 30%.","text":"Up fast, down also fast. Even Pfizer's price also not up more than 30%.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/375314661","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://www.laohu8.com/m/news/1122047796?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\n Motley Fool 2021-04-23 23:05\n\n</h4>\n</header>\n<article>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\"> Motley Fool </a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1,"symbols_score_info":{"INO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4124510,"gmtCreate":1619308936260,"gmtModify":1635512153549,"authorId":3576709266160370,"author":{"id":3576709266160370,"idStr":"3576709266160370","authorId":3576709266160370,"name":"AndyQuak","avatar":"https://static.tigerbbs.com/bd9f635e190b833549d9282c6e3e2f59","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375314661,"type":1,"supId":0,"prevId":0,"content":"comment thanks","text":"comment thanks","html":"comment thanks"}],"langContent":"EN"},{"id":375334046,"gmtCreate":1619306974185,"gmtModify":1634287257801,"author":{"id":"3580416813447115","authorId":"3580416813447115","name":"BeHappy","avatar":"https://static.tigerbbs.com/de3a06dde5f6ecf00082e1f076b52587","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3580416813447115","authorIdStr":"3580416813447115"},"htmlText":"I have no idea","listText":"I have no idea","text":"I have no idea","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/375334046","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://www.laohu8.com/m/news/1122047796?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\n Motley Fool 2021-04-23 23:05\n\n</h4>\n</header>\n<article>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\"> Motley Fool </a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1,"symbols_score_info":{"INO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":375303967,"gmtCreate":1619302905259,"gmtModify":1634287277877,"author":{"id":"3579917251051668","authorId":"3579917251051668","name":"Jusdidas","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3579917251051668","authorIdStr":"3579917251051668"},"htmlText":"Please like and comment!","listText":"Please like and comment!","text":"Please like and comment!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/375303967","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://www.laohu8.com/m/news/1122047796?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\n Motley Fool 2021-04-23 23:05\n\n</h4>\n</header>\n<article>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\"> Motley Fool </a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1,"symbols_score_info":{"INO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4124332,"gmtCreate":1619307499786,"gmtModify":1635512170269,"authorId":3563504647645776,"author":{"id":3563504647645776,"idStr":"3563504647645776","authorId":3563504647645776,"name":"Sandy92","avatar":"https://static.tigerbbs.com/9f86355f6dbed4dfca34d989df1a36e1","vip":1,"crmLevel":9,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375303967,"type":1,"supId":0,"prevId":0,"content":"done. please like and comment back","text":"done. please like and comment back","html":"done. please like and comment back"}],"langContent":"EN"},{"id":375977682,"gmtCreate":1619302248446,"gmtModify":1634287280018,"author":{"id":"3527303552443900","authorId":"3527303552443900","name":"458fd99c","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3527303552443900","authorIdStr":"3527303552443900"},"htmlText":"Why not","listText":"Why not","text":"Why not","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/375977682","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://www.laohu8.com/m/news/1122047796?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\n Motley Fool 2021-04-23 23:05\n\n</h4>\n</header>\n<article>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\"> Motley Fool </a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1,"symbols_score_info":{"INO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":375987580,"gmtCreate":1619277679440,"gmtModify":1634287317493,"author":{"id":"3582195961698597","authorId":"3582195961698597","name":"knowplay","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582195961698597","authorIdStr":"3582195961698597"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/375987580","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://www.laohu8.com/m/news/1122047796?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\n Motley Fool 2021-04-23 23:05\n\n</h4>\n</header>\n<article>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\"> Motley Fool </a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1,"symbols_score_info":{"INO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":375987840,"gmtCreate":1619277598680,"gmtModify":1634287317852,"author":{"id":"3581834128004381","authorId":"3581834128004381","name":"Poisonz","avatar":"https://static.tigerbbs.com/5e0dd20af13212be3d544bc41039e0fe","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3581834128004381","authorIdStr":"3581834128004381"},"htmlText":"Lol","listText":"Lol","text":"Lol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/375987840","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://www.laohu8.com/m/news/1122047796?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\n Motley Fool 2021-04-23 23:05\n\n</h4>\n</header>\n<article>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\"> Motley Fool </a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1,"symbols_score_info":{"INO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":375937133,"gmtCreate":1619274981622,"gmtModify":1634287332663,"author":{"id":"3580169073488033","authorId":"3580169073488033","name":"Crip","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3580169073488033","authorIdStr":"3580169073488033"},"htmlText":"Joke","listText":"Joke","text":"Joke","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/375937133","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://www.laohu8.com/m/news/1122047796?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\n Motley Fool 2021-04-23 23:05\n\n</h4>\n</header>\n<article>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\"> Motley Fool </a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1,"symbols_score_info":{"INO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4123362,"gmtCreate":1619279671648,"gmtModify":1635512251294,"authorId":3576561701314627,"author":{"id":3576561701314627,"idStr":"3576561701314627","authorId":3576561701314627,"name":"hellotomato","avatar":"https://static.tigerbbs.com/5a5be72959c7fb86f0212f7bbbbfbc84","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375937133,"type":1,"supId":0,"prevId":0,"content":":/","text":":/","html":":/"}],"langContent":"EN"},{"id":375990151,"gmtCreate":1619271608673,"gmtModify":1634287348657,"author":{"id":"3562800806331755","authorId":"3562800806331755","name":"DogeFather69","avatar":"https://static.tigerbbs.com/012eed43a063aef772d43c0a45a463d9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3562800806331755","authorIdStr":"3562800806331755"},"htmlText":"Wtf","listText":"Wtf","text":"Wtf","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/375990151","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://www.laohu8.com/m/news/1122047796?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\n Motley Fool 2021-04-23 23:05\n\n</h4>\n</header>\n<article>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\"> Motley Fool </a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1,"symbols_score_info":{"INO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":375908002,"gmtCreate":1619270411606,"gmtModify":1634287353849,"author":{"id":"3579092031958753","authorId":"3579092031958753","name":"mr_tig3r","avatar":"https://static.tigerbbs.com/333e3ca9288379f6071ce74d34fdb629","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3579092031958753","authorIdStr":"3579092031958753"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/375908002","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://www.laohu8.com/m/news/1122047796?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\n Motley Fool 2021-04-23 23:05\n\n</h4>\n</header>\n<article>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\"> Motley Fool </a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1,"symbols_score_info":{"INO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":375900315,"gmtCreate":1619269359637,"gmtModify":1634287356859,"author":{"id":"3575152506937716","authorId":"3575152506937716","name":"xuanlin","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3575152506937716","authorIdStr":"3575152506937716"},"htmlText":"Comment pls","listText":"Comment pls","text":"Comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/375900315","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://www.laohu8.com/m/news/1122047796?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\n Motley Fool 2021-04-23 23:05\n\n</h4>\n</header>\n<article>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\"> Motley Fool </a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1,"symbols_score_info":{"INO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4124929,"gmtCreate":1619311317952,"gmtModify":1635512112752,"authorId":3570439473038184,"author":{"id":3570439473038184,"idStr":"3570439473038184","authorId":3570439473038184,"name":"Qarah","avatar":"https://static.tigerbbs.com/48285a44928a897dd5f255c626d5e9e1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375900315,"type":1,"supId":0,"prevId":0,"content":"Done!","text":"Done!","html":"Done!"}],"langContent":"EN"},{"id":375045776,"gmtCreate":1619266813195,"gmtModify":1634287364574,"author":{"id":"3580980349710552","authorId":"3580980349710552","name":"justinC","avatar":"https://static.tigerbbs.com/b1df8f1b7bfcecfea836a18bee080563","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3580980349710552","authorIdStr":"3580980349710552"},"htmlText":"Like and commment please","listText":"Like and commment please","text":"Like and commment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/375045776","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://www.laohu8.com/m/news/1122047796?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\n Motley Fool 2021-04-23 23:05\n\n</h4>\n</header>\n<article>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\"> Motley Fool </a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1,"symbols_score_info":{"INO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4122481,"gmtCreate":1619266846808,"gmtModify":1635512326666,"authorId":3580980349710552,"author":{"id":3580980349710552,"idStr":"3580980349710552","authorId":3580980349710552,"name":"justinC","avatar":"https://static.tigerbbs.com/b1df8f1b7bfcecfea836a18bee080563","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375045776,"type":1,"supId":0,"prevId":0,"content":"ple","text":"ple","html":"ple"}],"langContent":"EN"},{"id":375051553,"gmtCreate":1619264281572,"gmtModify":1634287375166,"author":{"id":"3560092322694803","authorId":"3560092322694803","name":"dahae","avatar":"https://static.tigerbbs.com/137beae1f6048901843924ba46796740","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3560092322694803","authorIdStr":"3560092322694803"},"htmlText":"comment pls&nbsp;","listText":"comment pls&nbsp;","text":"comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/375051553","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://www.laohu8.com/m/news/1122047796?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\n Motley Fool 2021-04-23 23:05\n\n</h4>\n</header>\n<article>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\"> Motley Fool </a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1,"symbols_score_info":{"INO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4123799,"gmtCreate":1619301058896,"gmtModify":1635512213867,"authorId":3578965435978206,"author":{"id":3578965435978206,"idStr":"3578965435978206","authorId":3578965435978206,"name":"pandajojo","avatar":"https://static.tigerbbs.com/7efe44a2514d987c5a8b342b85d6f229","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375051553,"type":1,"supId":0,"prevId":0,"content":"Like n comment","text":"Like n comment","html":"Like n comment"},{"id":4129346,"gmtCreate":1619346997672,"gmtModify":1635511690223,"authorId":3560092322694803,"author":{"id":3560092322694803,"idStr":"3560092322694803","authorId":3560092322694803,"name":"dahae","avatar":"https://static.tigerbbs.com/137beae1f6048901843924ba46796740","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375051553,"type":1,"supId":4123799,"prevId":0,"content":".","text":".","html":"."},{"id":4129376,"gmtCreate":1619347356470,"gmtModify":1635511687293,"authorId":3560092322694803,"author":{"id":3560092322694803,"idStr":"3560092322694803","authorId":3560092322694803,"name":"dahae","avatar":"https://static.tigerbbs.com/137beae1f6048901843924ba46796740","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375051553,"type":1,"supId":4123799,"prevId":0,"content":".","text":".","html":"."}],"langContent":"EN"},{"id":375064086,"gmtCreate":1619261087145,"gmtModify":1634287386638,"author":{"id":"3582161778784599","authorId":"3582161778784599","name":"Ivylow","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3582161778784599","authorIdStr":"3582161778784599"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/375064086","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://www.laohu8.com/m/news/1122047796?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\n Motley Fool 2021-04-23 23:05\n\n</h4>\n</header>\n<article>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\"> Motley Fool </a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1,"symbols_score_info":{"INO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":375065464,"gmtCreate":1619261062558,"gmtModify":1634287386759,"author":{"id":"3582161778784599","authorId":"3582161778784599","name":"Ivylow","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3582161778784599","authorIdStr":"3582161778784599"},"htmlText":"$","listText":"$","text":"$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/375065464","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://www.laohu8.com/m/news/1122047796?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\n Motley Fool 2021-04-23 23:05\n\n</h4>\n</header>\n<article>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\"> Motley Fool </a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1,"symbols_score_info":{"INO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":375065642,"gmtCreate":1619261038586,"gmtModify":1634287386880,"author":{"id":"3582161778784599","authorId":"3582161778784599","name":"Ivylow","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3582161778784599","authorIdStr":"3582161778784599"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/375065642","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://www.laohu8.com/m/news/1122047796?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\n Motley Fool 2021-04-23 23:05\n\n</h4>\n</header>\n<article>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\"> Motley Fool </a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1,"symbols_score_info":{"INO":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":235,"commentSize":50,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}